Headlines about Kamada (NASDAQ:KMDA) have trended somewhat positive on Monday, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Kamada earned a news impact score of 0.15 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 45.2621880989997 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern’s scoring:
- Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection (finance.yahoo.com)
- Kamada (KMDA) Raised to “Hold” at ValuEngine (americanbankingnews.com)
- Kamada (KMDA) & Cesca Therapeutics (KOOL) Critical Analysis (americanbankingnews.com)
- Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease (finance.yahoo.com)
Shares of Kamada (NASDAQ:KMDA) traded down $0.05 during mid-day trading on Monday, reaching $5.20. The company’s stock had a trading volume of 21,900 shares, compared to its average volume of 26,100. The company has a quick ratio of 2.73, a current ratio of 3.71 and a debt-to-equity ratio of 0.02. The stock has a market cap of $209.71, a price-to-earnings ratio of -129.97 and a beta of 1.03. Kamada has a 12 month low of $3.75 and a 12 month high of $8.61.
A number of research analysts have recently issued reports on KMDA shares. Jefferies Group reiterated a “buy” rating and set a $7.00 target price on shares of Kamada in a research report on Thursday, October 12th. Zacks Investment Research upgraded Kamada from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. Finally, ValuEngine upgraded Kamada from a “sell” rating to a “hold” rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $8.50.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://transcriptdaily.com/2018/01/08/kamada-kmda-receiving-somewhat-positive-media-coverage-accern-reports.html.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.